Table 3 Multiple Cox regression analyses for progression-free and overall survival, both for the proportion of explained variations of clinicopathologic parameters and FAK as well as pFAK for late stage serous ovarian cancer patients (n = 172)

1.48 (1.22-1.79)

<0.001

1.35 (1.08-1.69)

0.010

2.48 (1.51-4.06)

<0.001

3.35 (1.84-6.09)

<0.001

1.56 (0.91-2.68)

0.105

1.64 (0.83-3.24)

0.155

1.77 (1.12-2.78)

0.014

1.33 (0.78-2.24)

0.292

3.11 (1.64-5.90)

<0.001

3.18 (1.43-7.11)

0.005

2.51 (1.49-4.24)*

0.001

2.23 (1.29-3.87)

0.004

0.85 (0.41-1.77)

0.671

0.91 (0.37-2.24)

0.830

0.80 (0.50-1.27)

0.343

0.54 (0.31-0.96)

0.034

Univariate, n = 172

Multiple, n = 140

HR (CI 95%)

p

HR (CI 95%)

p

1.25 (1.08-1.44)

0.003

1.19 (1.01-1.41)

0.042

2.81 (1.83-4.31)

<0.001

3.04 (1.83-5.06)

<0.001

1.32 (0.89-1.97)

0.171

1.01 (0.61-1.66)

0.971

1.94 (1.35-2.81)

<0.001

1.40 (0.91-2.17)

0.127

2.77 (1.78-4.32)

<0.001

3.13 (1.80-5.46)

<0.001

1.61 (1.09-2.36)**

0.016

1.36 (0.90-2.04)

0.142

0.87 (0.48-1.58)

0.654

0.89 (0.41-1.95)

0.776

1.15 (0.81-1.63)

0.425

1.02 (0.66-1.57)

0.927